DR. JOHN J MURPHY, M.D.
Medical Practice at Fruitvale Ave, Oakland, CA
License number
California A99461
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California 46482
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California 46482
Category
Medical Practice
Type
Pediatrics
Address
Address
1515 Fruitvale Ave, Oakland, CA 94601
Phone
(510) 535-6300
(510) 535-4019 (Fax)
(510) 535-4000
(510) 535-4128 (Fax)
(510) 535-4019 (Fax)
(510) 535-4000
(510) 535-4128 (Fax)
Personal information
See more information about JOHN J MURPHY at radaris.comName
Address
Phone
501 Kinglet Ct, Suisun City, CA 94585
5004 N Greenpark Ave, Covina, CA 91724
5003 Shalimar Cir, Fremont, CA 94555
5031 Creek View Way, Sacramento, CA 95841
507 Lassen St, South San Francisco, CA 94080
Professional information
John Murphy - Oakland, CA
Work:
East Bay Express - Oakland, CA
Circulation Manager Action Movers - Oakland, CA
Mover phomenow.com - Berkeley, CA
Food Delivery Driver Lanesplitter Pizza - Albany, CA
Food Delivery Driver, Cashier, Food Prep Lanesplitter Pizza - Castro Valley, CA
Sales Representative
Circulation Manager Action Movers - Oakland, CA
Mover phomenow.com - Berkeley, CA
Food Delivery Driver Lanesplitter Pizza - Albany, CA
Food Delivery Driver, Cashier, Food Prep Lanesplitter Pizza - Castro Valley, CA
Sales Representative
Education:
San Francisco State University - San Francisco, CA
Bachelors in Liberal Arts San Rafael High School
Bachelors in Liberal Arts San Rafael High School
John J Murphy, Oakland CA
Specialties:
Internist
Address:
1515 Fruitvale Ave, Oakland, CA 94601
1601 Fruitvale Ave, Oakland, CA 94601
1601 Fruitvale Ave, Oakland, CA 94601
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Pediatrics Certification in Pediatrics
Lipid-Conjugated Polyamide Compounds And Related Compositions And Methods Thereof
US Patent:
6572881, Jun 3, 2003
Filed:
Jul 21, 2000
Appl. No.:
09/620259
Inventors:
Ronald N. Zuckermann - Berkeley CA
Chin-Yi Huang - Fremont CA
John E. Murphy - Oakland CA
Tetsuo Uno - San Francisco CA
Chin-Yi Huang - Fremont CA
John E. Murphy - Oakland CA
Tetsuo Uno - San Francisco CA
Assignee:
Chiron Corporation - Emeryville CA
International Classification:
A61K 9127
US Classification:
424450, 552502, 552544, 524728, 554 35, 554 36, 554 37, 554 79, 935 52, 935 54
Abstract:
In accordance with the present invention, there are provided lipid-conjugated polyamide compounds and related compositions and methods thereof. Lipid-conjugated polyamide compounds of the present invention are particularly useful as vehicles for delivering biologically active agents to a target site. In particular, the invention compounds are effective at facilitating the delivery of polynucleotides to cells. The present invention also provides a method for producing stable formulations of polynucleotides complexed with a delivery vehicle.
Lipid-Conjugated Polyamide Compounds And Related Compositions And Methods Thereof
US Patent:
6569450, May 27, 2003
Filed:
Jul 21, 2000
Appl. No.:
09/620260
Inventors:
Ronald N. Zuckermann - Berkeley CA
Chin-Yi Huang - Fremont CA
John E. Murphy - Oakland CA
Tetsuo Uno - San Francisco CA
Chin-Yi Huang - Fremont CA
John E. Murphy - Oakland CA
Tetsuo Uno - San Francisco CA
Assignee:
Chiron Corporation - Emeryville CA
International Classification:
A61K 9127
US Classification:
424450, 552502, 552544, 524728, 554 35, 554 36, 554 37, 554 79, 935 52, 935 54
Abstract:
In accordance with the present invention, there are provided lipid-conjugated polyamide compounds and related compositions and methods thereof. Lipid-conjugated polyamide compounds of the present invention are particularly useful as vehicles for delivering biologically active agents to a target site. In particular, the invention compounds are effective at facilitating the delivery of polynucleotides to cells. The present invention also provides a method for producing stable formulations of polynucleotides complexed with a delivery vehicle.
Human Antibodies That Have Mn Binding And Cell Adhesion-Neutralizing Activity
US Patent:
2010024, Sep 23, 2010
Filed:
Dec 8, 2008
Appl. No.:
12/330504
Inventors:
Toshihiko Takeuchi - Oakland CA, US
John E. Murphy - Oakland CA, US
Julie Rinkenberger - Moraga CA, US
John E. Murphy - Oakland CA, US
Julie Rinkenberger - Moraga CA, US
International Classification:
C12P 21/00, C07H 21/04, C12N 15/74, C12N 5/10
US Classification:
435 696, 536 2353, 4353201, 435326
Abstract:
The invention is composed of monoclonal human MN antibodies or MN antibody fragments that target the GEEDLP repeat within the proteoglycan domain. The proteoglycan domain of the MN cell surface protein contains four of these identical GEEDLP repeats. Binding to the desired epitope is verified by competition ELISA, where ELISA signal can be attenuated by co-incubation with a peptide containing this repeat (PGEEDLPGEEDLP). This inhibition of binding can also be verified using Biacore assays, where binding of desired antibodies to immobilized MN or proteoglycan peptides can be inhibited by the peptide repeat. In addition to binding to the peptide repeat, human anti-MN antibodies can inhibit the cell adhesion of CGL-1 cells to MN coated plastic plates. Human anti-MN antibodies have been used to diagnose and quantify MN expression in cancer cells and tumors using FACS and immunohistochemical methods. An example is also provided where a human anti-MN IgG1 mediates tumor cell lysis though antibody-dependent cell-mediated cytotoxicity. Therefore, these antibodies will be useful for the treatment of cancers in which MN is upregulated or can be useful for the diagnosis of cancers in which MN is upregulated.
Human Antibodies That Have Mn Binding And Cell Adhesion-Neutralizing Activity
US Patent:
7462696, Dec 9, 2008
Filed:
Oct 18, 2002
Appl. No.:
10/273541
Inventors:
Toshihiko Takeuchi - Oakland CA, US
John E. Murphy - Oakland CA, US
Julie Rinkenberger - Moraga CA, US
John E. Murphy - Oakland CA, US
Julie Rinkenberger - Moraga CA, US
Assignee:
Bayer Pharmaceutical Corporation - West Haven CT
International Classification:
C07K 16/46, C07K 16/24
US Classification:
5303873, 53038823, 5303887
Abstract:
The invention is composed of monoclonal human MN antibodies or MN antibody fragments that target the GEEDLP (SEQ ID NO: 118) repeat within the proteoglycan domain. The proteoglycan domain of the MN cell surface protein contains four of these identical GEEDLP (SEQ ID NO: 118) repeats. Binding to the desired epitope is verified by competition ELISA, where ELISA signal can be attenuated by co-incubation with a peptide containing this repeat (PGEEDLPGEEDLP (SEQ ID NO: 119)). This inhibition of binding can also be verified using Biacore assays, where binding of desired antibodies to immobilized MN or proteoglycan peptides can be inhibited by the peptide repeat. In addition to binding to the peptide repeat, human anti-MN antibodies can inhibit the cell adhesion of CGL-1 cells to MN coated plastic plates. Human anti-MN antibodies have been used to diagnose and quantify MN expression in cancer cells and tumors using FACS and immunohistochemical methods. An example is also provided where a human anti-MN IgG1 mediates tumor cell lysis though antibody-dependent cell-mediated cytotoxicity.
Polycationic Polymers
US Patent:
6251433, Jun 26, 2001
Filed:
Aug 13, 1997
Appl. No.:
8/910647
Inventors:
Ronald N. Zuckermann - Berkeley CA
Varavani Dwarki - Alameda CA
Michael A. Innis - Moraga CA
John E. Murphy - Oakland CA
Fred E. Cohen - San Francisco CA
Tetsuo Uno - San Francisco CA
Varavani Dwarki - Alameda CA
Michael A. Innis - Moraga CA
John E. Murphy - Oakland CA
Fred E. Cohen - San Francisco CA
Tetsuo Uno - San Francisco CA
Assignee:
Chiron Corporation - Emeryville CA
International Classification:
A61F 914
US Classification:
424486
Abstract:
This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.
Lipid-Conjugated Polyamide Compounds And Related Compositions And Methods Thereof
US Patent:
6197332, Mar 6, 2001
Filed:
Aug 12, 1998
Appl. No.:
9/132808
Inventors:
Ronald N. Zuckermann - Berkeley CA
Chin-Yi Huang - Fremont CA
John E. Murphy - Oakland CA
Tetsuo Uno - San Francisco CA
Chin-Yi Huang - Fremont CA
John E. Murphy - Oakland CA
Tetsuo Uno - San Francisco CA
Assignee:
Chiron Corporation - Emeryville CA
International Classification:
A61K 9127
US Classification:
424450
Abstract:
In accordance with the present invention, there are provided lipid-conjugated polyamide compounds and related compositions and methods thereof. Lipid-conjugated polyamide compounds of the present invention are particularly useful as vehicles for delivering biologically active agents to a target site. In particular, the invention compounds are effective at facilitating the delivery of polynucleotides to cells. The present invention also provides a method for producing stable formulations of polynucleotides complexed with a delivery vehicle.
Method Of Complexing A Nucleic Acid With A Lipid-Conjugated Polyamide
US Patent:
6982092, Jan 3, 2006
Filed:
May 30, 2003
Appl. No.:
10/448902
Inventors:
Ronald N. Zuckermann - Berkeley CA, US
Chin-Yi Huang - Fremont CA, US
John E. Murphy - Oakland CA, US
Tetsuo Uno - San Francisco CA, US
Chin-Yi Huang - Fremont CA, US
John E. Murphy - Oakland CA, US
Tetsuo Uno - San Francisco CA, US
Assignee:
Chiron Corporation - Emeryville CA
International Classification:
A61K 9/127, C07H 21/04, C07J 9/00, C08K 5/21, C11C 3/00
US Classification:
424450, 536 231, 552502, 552544, 524728, 554 35, 554 36, 554 37, 554 79
Abstract:
In accordance with the present invention, there are provided lipid-conjugated polyamide compounds and related compositions and methods thereof. Lipid-conjugated polyamide compounds of the present invention are particularly useful as vehicles for delivering biologically active agents to a target site. In particular, the invention compounds are effective at facilitating the delivery of polynucleotides to cells. The present invention also provides a method for producing stable formulations of polynucleotides complexed with a delivery vehicle.
Compositions And Methods For Polynucleotide Delivery
US Patent:
7462592, Dec 9, 2008
Filed:
Oct 22, 2002
Appl. No.:
10/278751
Inventors:
Ronald N. Zuckermann - Berkeley CA, US
Varavani Dwarki - Alameda CA, US
Michael A. Innis - Moraga CA, US
John E. Murphy - Oakland CA, US
Fred E. Cohen - San Francisco CA, US
Tetsuo Uno - San Francisco CA, US
Varavani Dwarki - Alameda CA, US
Michael A. Innis - Moraga CA, US
John E. Murphy - Oakland CA, US
Fred E. Cohen - San Francisco CA, US
Tetsuo Uno - San Francisco CA, US
Assignee:
Novartis Vaccines and Diagnostics, Inc. - Emeryville CA
International Classification:
A01N 37/18, A61K 9/14, A61K 38/00
US Classification:
514 2, 424486, 530300
Abstract:
This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.